Welcome to our dedicated page for Turn Therapeutics news (Ticker: TTRX), a resource for investors and traders seeking the latest updates and insights on Turn Therapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Turn Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Turn Therapeutics's position in the market.
Turn Therapeutics (Nasdaq: TTRX) reported third-quarter 2025 results and corporate updates on November 13, 2025. Key developments include beginning Nasdaq trading on October 8, 2025, a global supply, development, and license agreement with Medline, two new board appointments, and a new VP of corporate communications.
Operational updates: commenced a clinical trial of a topical IL-36/IL-31 inhibitor for eczema and reported intranasal vaccine stability of 14 days at ambient temperature and 28 days under refrigeration. Financials: Q3 net loss $1.904M, R&D $158,699, G&A $1.754M, and cash $3.106M as of September 30, 2025.
Turn Therapeutics (Nasdaq: TTRX) announced that CEO Bradley Burnam spoke with Dr. Robert Redfield, former CDC director, on Nov 11, 2025 about healthcare communications and restoring public trust in science.
The interview, titled "Redfield’s Warning: Former CDC Director on COVID’s Biggest Casualty-Trust in Science", is available on major podcast platforms, YouTube, and the Turn Therapeutics investor relations website. The conversation emphasizes fact-based science, data-driven public health messaging, and continued dialogue between biotech leaders and public officials.
Dr. Redfield is described as a virologist who led CDC from 2018–2021 and contributed to early HIV research including the Walter Reed staging system and evidence of active HIV replication across disease stages.
Turn Therapeutics (Nasdaq: TTRX) said its topical IL-36/IL-31 inhibitor GX-03 was named one of “Five Novel Mechanisms Reshaping Atopic Dermatitis Treatment” by Patient Care Online on Nov 11, 2025. The company said GX-03 is the first topical agent targeting IL-36 and demonstrated inhibition of IL-36 alpha, IL-31, IL-4, and IL-36 gamma. Turn described GX-03 as a potential alternative to systemic and injectable therapies for eczema and psoriasis. The company also said it expects to announce topline data from its lead severe eczema program in early 2026.
Patient Care Online is described as a clinical news resource for office-based clinicians covering drug approvals, research commentary, and clinical trial highlights.
Turn Therapeutics (Nasdaq: TTRX) announced on November 4, 2025 the appointment of Andrew Scott as Vice President of Corporate Communications.
Mr. Scott will oversee investor relations, capital markets strategy, and corporate communications, and will support the company’s licensing and partnership initiatives as Turn advances toward the completion of its Phase 2 clinical program. He joins after a 30-year capital markets career, including a Managing Director role at ThinkEquity and prior business development work at Fortress Biosciences, and has helped raise approximately $3 billion across life-sciences transactions.
Turn Therapeutics (Nasdaq: TTRX) on October 30, 2025 announced a global supply, development, and license agreement with Medline to combine Turn's PermaFusion® delivery platform with Medline's scale and distribution.
The collaboration establishes a long-term partnership to develop, manufacture, and commercialize professional and consumer products; financial terms, specific product categories, and timelines are confidential. The company said it will provide updates as joint initiatives progress toward commercialization and as development milestones are achieved.
Turn Therapeutics (Nasdaq: TTRX) provided a shareholder update on October 22, 2025 outlining clinical progress and a flexible capital plan following a dilution-sparing direct listing.
Key items: a $85 million GEM Global Yield agreement provides on-demand financing; the randomized Phase 2 trial of topical GX-03 for moderate to severe eczema is ~25% complete with >1,000 confirmed study product applications and a blinded aggregate safety summary reporting no safety or tolerability concerns to date; topline GX-03 results are anticipated in 2026. Turn also plans in‑vivo studies for a thermostable intranasal vaccine initiative in Q4 2025. The company hosted a shareholder webinar on October 22, 2025 at 2:00 PM ET.
Turn Therapeutics (Nasdaq: TTRX) launched a shareholder communications initiative including a recurring webinar series and a Founder Blog by CEO Bradley Burnam.
The first live webinar is scheduled for October 22, 2025 at 2:00 PM ET via webcast; recordings and materials will be posted to the investor relations website immediately after each session. The Founder Blog will share ongoing company updates, research insights, and perspectives, with additional blog details to be announced later this week.
Turn notes three FDA clearances for its wound and dermatology formulations and ongoing late-stage clinical programs in eczema and onychomycosis.
Turn Therapeutics (NASDAQ:TTRX) announced on October 15, 2025 that Kent E. Kester, MD, FACP, FIDSA, FASTMH, has been appointed to its Board of Directors.
Dr. Kester is described as a retired U.S. Army Colonel and an infectious disease physician with senior leadership experience in clinical development, translational medicine, vaccine and anti-infective innovation, and public-private global health collaborations, including service as Commander of the Walter Reed Army Institute of Research. The company said his experience will support late-stage programs, regulatory milestones, governance, and strategic direction as Turn advances its dermatology, wound, and anti-infective therapies.
Turn Therapeutics (NASDAQ:TTRX) appointed Arthur Golden to its Board of Directors effective Oct 14, 2025. Mr. Golden brings corporate governance and legal expertise, including 24 years as a director at Emerson Electric and more than 40 years as a partner and now Senior Counsel at Davis Polk & Wardwell. The company said his experience in M&A, shareholder relations, compliance, and cross-border governance will support oversight as Turn advances its late-stage dermatology, wound, and anti-infective programs.
The CEO framed the hire as strengthening governance, strategic execution, and capital-market navigation during a critical growth inflection for the company.
Turn Therapeutics (NASDAQ:TTRX) announced its common stock will commence trading today, October 8, 2025, on the Nasdaq Capital Market under the ticker TTRX.
The company's Form S-1 was declared effective by the SEC on September 30, 2025. Founder and CEO Bradley Burnam will participate in a Closing Bell ceremony at 4:00 PM ET on October 8, 2025, broadcast live from Nasdaq MarketSite. Financial advisor and legal counsel were named: Clear Street LLC (financial advisor) and Davis Polk and Wardwell (legal counsel).
FAQ
What is the current stock price of Turn Therapeutics (TTRX)?
What is the market cap of Turn Therapeutics (TTRX)?
